Department of Cardiac Surgery, Royal Children's Hospital, Melbourne, Australia.
Pediatr Crit Care Med. 2013 Jun;14(5 Suppl 1):S69-72. doi: 10.1097/PCC.0b013e318292e332.
Remarkable outcomes have been reported after prolonged mechanical circulatory support in the pediatric population, but there is yet no clear delineation of the duration beyond which supporting a child becomes futile. The likelihood of survival in patients supported on extracorporeal membrane oxygenation for respiratory failure decreases with the length of support. However, extracorporeal membrane oxygenation can be successfully used in these patients for long periods (weeks to months) provided adequate support is maintained without complications. This is not the case with cardiac failure and mechanical circulatory support.Extracorporeal membrane oxygenation is usually the initial form of mechanical circulatory support used in patients with primary refractory myocardial dysfunction. There is evidence and consensus that if the patient shows no signs of recovery after a maximum duration of 2 weeks, he or she should be transitioned to a ventricular assist device, which allows prolonged support. In post-cardiac surgery patients, survival is only anecdotal beyond 12 days of extracorporeal membrane oxygenation support, and myocardial recovery is exceptionally rare after this time period unless new diagnoses and management strategies are formulated.Repeat extracorporeal membrane oxygenation should generally not be offered to patients unless it is established that support was withdrawn prematurely or a new intervention is planned. Repeat extracorporeal membrane oxygenation may achieve some improvement in early survival, but the long-term outcomes of survivors are so poor that these attempts cannot be generally recommended unless organ transplantation is an option.
在儿科人群中,长时间机械循环支持后已报告了显著的结果,但仍没有明确界定支持儿童的时间超过多长时间是徒劳的。在因呼吸衰竭接受体外膜氧合支持的患者中,支持时间越长,生存的可能性越低。然而,如果没有并发症且维持适当的支持,体外膜氧合可以在这些患者中长时间(数周到数月)成功使用。心力衰竭和机械循环支持则并非如此。体外膜氧合通常是用于原发性难治性心肌功能障碍患者的初始机械循环支持形式。有证据和共识表明,如果患者在最长 2 周的时间内没有任何恢复迹象,他或她应过渡到心室辅助装置,以进行长时间支持。在心脏手术后患者中,体外膜氧合支持超过 12 天的生存情况仅为传闻,并且在这段时间之后,除非制定新的诊断和管理策略,否则心肌恢复非常罕见。除非支持被过早撤回或计划进行新的干预,否则一般不应向患者提供重复的体外膜氧合。重复体外膜氧合可能会在早期生存方面取得一些改善,但幸存者的长期结局非常差,除非器官移植是一种选择,否则这些尝试不能普遍推荐。